Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Retraction Free access | 10.1172/JCI63366

Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice

Fei Wang, Yasuo Okamoto, Isao Inoki, Kazuaki Yoshioka, Wa Du, Xun Qi, Noriko Takuwa, Koichi Gonda, Yasuhiko Yamamoto, Ryunosuke Ohkawa, Takumi Nishiuchi, Naotoshi Sugimoto, Yutaka Yatomi, Kunitoshi Mitsumori, Masahide Asano, Makoto Kinoshita, and Yoh Takuwa

Find articles by Wang, F. in: JCI | PubMed | Google Scholar

Find articles by Okamoto, Y. in: JCI | PubMed | Google Scholar

Find articles by Inoki, I. in: JCI | PubMed | Google Scholar

Find articles by Yoshioka, K. in: JCI | PubMed | Google Scholar

Find articles by Du, W. in: JCI | PubMed | Google Scholar

Find articles by Qi, X. in: JCI | PubMed | Google Scholar

Find articles by Takuwa, N. in: JCI | PubMed | Google Scholar

Find articles by Gonda, K. in: JCI | PubMed | Google Scholar

Find articles by Yamamoto, Y. in: JCI | PubMed | Google Scholar

Find articles by Ohkawa, R. in: JCI | PubMed | Google Scholar

Find articles by Nishiuchi, T. in: JCI | PubMed | Google Scholar

Find articles by Sugimoto, N. in: JCI | PubMed | Google Scholar

Find articles by Yatomi, Y. in: JCI | PubMed | Google Scholar

Find articles by Mitsumori, K. in: JCI | PubMed | Google Scholar

Find articles by Asano, M. in: JCI | PubMed | Google Scholar

Find articles by Kinoshita, M. in: JCI | PubMed | Google Scholar

Find articles by Takuwa, Y. in: JCI | PubMed | Google Scholar

Published March 1, 2012 - More info

Published in Volume 122, Issue 3 on March 1, 2012
J Clin Invest. 2012;122(3):1131–1131. https://doi.org/10.1172/JCI63366.
© 2012 The American Society for Clinical Investigation
Published March 1, 2012 - Version history
View PDF

Related article:

Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice
Fei Wang, … , Makoto Kinoshita, Yoh Takuwa
Fei Wang, … , Makoto Kinoshita, Yoh Takuwa
Research Article Cardiology

Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice

  • Text
  • PDF
Abstract

Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid that has pleiotropic effects in a variety of cell types including ECs, SMCs, and macrophages, all of which are central to the development of atherosclerosis. It may therefore exert stimulatory and inhibitory effects on atherosclerosis. Here, we investigated the role of the S1P receptor S1PR2 in atherosclerosis by analyzing S1pr2–/– mice with an Apoe–/– background. S1PR2 was expressed in macrophages, ECs, and SMCs in atherosclerotic aortas. In S1pr2–/–Apoe–/– mice fed a high-cholesterol diet for 4 months, the area of the atherosclerotic plaque was markedly decreased, with reduced macrophage density, increased SMC density, increased eNOS phosphorylation, and downregulation of proinflammatory cytokines compared with S1pr2+/+Apoe–/– mice. Bone marrow chimera experiments indicated a major role for macrophage S1PR2 in atherogenesis. S1pr2–/–Apoe–/– macrophages showed diminished Rho/Rho kinase/NF-κB (ROCK/NF-κB) activity. Consequently, they also displayed reduced cytokine expression, reduced oxidized LDL uptake, and stimulated cholesterol efflux associated with decreased scavenger receptor expression and increased cholesterol efflux transporter expression. S1pr2–/–Apoe–/– ECs also showed reduced ROCK and NF-κB activities, with decreased MCP-1 expression and elevated eNOS phosphorylation. Pharmacologic S1PR2 blockade in S1pr2+/+Apoe–/– mice diminished the atherosclerotic plaque area in aortas and modified LDL accumulation in macrophages. We conclude therefore that S1PR2 plays a critical role in atherogenesis and may serve as a novel therapeutic target for atherosclerosis.

Authors

Fei Wang, Yasuo Okamoto, Isao Inoki, Kazuaki Yoshioka, Wa Du, Xun Qi, Noriko Takuwa, Koichi Gonda, Yasuhiko Yamamoto, Ryunosuke Ohkawa, Takumi Nishiuchi, Naotoshi Sugimoto, Yutaka Yatomi, Kunitoshi Mitsumori, Masahide Asano, Makoto Kinoshita, Yoh Takuwa

×

Original citation: J. Clin. Invest. 2010;120(11):3979–3995. doi:10.1172/JCI42315.

Citation for this retraction: J. Clin. Invest. 2012;122(3):1131. doi:10.1172/JCI63366.

All authors agree to retract the above article due to multiple use of the same images or manipulation of data in Figures 1A, 2D, 5C, 6B, 6C, and 8A and Supplemental Figure 8E. They are also not able to provide some of the raw data that are used in Figures 2A, 2B, 5, 6, 7C, 8, and 9C, Supplemental Tables 1–4, and Supplemental Figures 2C, 3, 4, 5, 7C, 8A–8C, 8E, 8F, 10A, and 10B. The first author, Fei Wang, has admitted his sole responsibility in altering figures. The authors apologize and deeply regret the impact of this action. However, the authors stand behind data showing that genetic deletion of S1pr2 or pharmacological S1PR2 inhibition alleviates atherosclerosis in Apoe–/– mice fed a high-cholesterol diet.

Version history
  • Version 1 (March 1, 2012): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts